Walvax沃森生物

About Us
Value of Vaccines
Products
R＆D
- R&D Platform
- Pipeline
Investors
Media
Collaborations
Career
Responsibility

About Us
Value of Vaccines
Products
R＆D
- R&D Platform
- Pipeline
Investors
Media
Collaborations
Career
Responsibility

CN
EN

Our Journey

Home About Us Our Journey

Over the past two decades, Walvax has achieved many milestones in developing vaccines.

2021
2020
2019
2018
2017
2015
2012
2010
2009
2007
2004
2001

2021

In 2021, SARS-CoV-2 mRNA Vaccine entered Phase Ⅲ clinical trial, and Recombinant SARS-CoV-2 Vaccine (Chimpanzee Adenoviral Vector) which is co-developed with Tsinghua University and Tianjin Medical University entered Phase Ⅰ clinical trial. Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Pichia pastoris) is expected to launch in the near future.

2020

In 2020, the application for manufacturing license of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris) was officially accepted by Chinese National Medical Products Administration (NMPA). Walvax’s SARS-CoV-2 mRNA Vaccine which is co-developed with Chinese Military Academy of Science and Abogen Biosciences entered Phase Ⅰ clinical trial.

2019

In 2019, Walvax identified 10-year development strategy which is to achieve internationalization, Industry 4.0 and import substitution. 13-valent Pneumococcal Polysaccharide Conjugate Vaccine was launched.

2018

In 2018, Group A and C Meningococcal Polysaccharide Vaccine (MPV AC) got Egypt Import Registration Approval and was included in Egypt EPI.

2017

In 2017, Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine were launched, and Group ACYW135 Meningococcal Polysaccharide Vaccine was awarded Halal certification issued by Majelis Ulama Indonesia (MUI).

2015

In 2015, Walvax built partnership with Bill & Melinda Gates Foundation and received USD5 million to expedite HPV vaccines' development process for WHO prequalification.

2012

In 2012, Group A and C Meningococcal Polysaccharide Vaccine and Group ACYW135 Meningococcal Polysaccharide Vaccine were launched, and Haemophilus Influenzae Type b Conjugate Vaccine was officially exported to the Philippines.

2010

In 2010, Walvax was listed on the Growth Enterprise Market (GEM) of Shenzhen Stock Exchange (SZSE). The stock name is abbreviated to “Walvax Biotechnology”, with the stock code of “300142”.

2009

In 2009, Group A and Group C Meningococcal Conjugate Vaccine was launched.

2007

In 2007, Walvax’s first independently developed and industrialized vaccine product, Haemophilus Influenzae Type b Conjugate Vaccine, was launched.

2004

In 2004, Walvax commenced the construction of Yuxi Vaccine Manufacturing Site.

2001

In 2001, Walvax was founded.

Add.

4/F, Bldg. A3, Yunnan University Science Park, No.269 Kefa Road, High & New Tech Dev. Zone, Kunming, Yunnan, China

Tel.

+ (86)871-63330984 68312889 68312126
(Monday through Friday 9:00 a.m. to 5:00 p.m. GMT+8)

Quick Links

About Walvax
Marketed Products
Pipeline
Contact Us

Follow Us

© 2021 Walvax Biotechnology Co., Ltd. 滇ICP备10201507号-1 Designed by Sumaart

Back To Top